#Genmab
Genmab Nine Month Revenue Rises 22 Percent to 3.24 Billion Dollars as EPKINLY Sales Jump 47 Percent

Genmab grew nine month revenue 22 percent to 3.238 billion dollars as DARZALEX royalties and a 47 percent jump in EPKINLY sales offset flat operating profit, and it kept full year guidance in place.
Genmab Nine Month Revenue Rises 22 Percent to 3.24 Billion Dollars as EPKINLY Sales Jump 47 Percent
Genmab grew nine month revenue 22 percent to 3.238 billion dollars as DARZALEX royalties and a 47 percent jump in EPKINLY sales offset flat operating profit, and it kept full year guidance in place.
qncnews.com
November 9, 2026 at 1:32 AM
$GMAB: Genmab reported Q3 revenue of $1.187B and nine-month revenue up 22% to $3.24B; 2026 guidance was maintained. Not investment advice.

https://www.merlintrader.com/genmab-gmab-stock-hub/
November 8, 2026 at 12:00 PM
$GMAB #Ratings #Biotech — Moody's revises Genmab outlook to positive, affirms Ba2 corporate family rating
https://justcharts.merlintrader.com/?utm_source=bluesky&utm_medium=social&utm_campaign=jc20261107&utm_content=GMAB#GMAB
Visit Justcharts for bull/bear scenarios.
$53.63, +1.7%. RSI 71.
November 7, 2026 at 5:49 AM
Genmab: 9M revenue $3.238B, op. profit $986M, OCF $574M; cash $1.860B, borrowings $4.992B; ASH epcoritamab Dec 12–15.

#$GMAB FAQ + PDF report: www.merlintrader.com/genmab-gmab-...
GMAB Stock: Genmab News, Antibodies & Oncology
Genmab stock news and analysis: petosemtamab, Rina-S and epcoritamab evidence, royalty economics, cash, acquisition debt and the regulatory risks for GMAB.
www.merlintrader.com
November 5, 2026 at 7:40 PM
Anti-LRG5 x anti-EGFR Petosemtamab by @Genmab @sitcancer.bsky.social #SITC2026 shows activity in second line against corectal cancer in combination with chemotherapy. This is an emerging theme at this meeting. Bispecifics+chemo showing increase potency
November 5, 2026 at 6:00 PM
Genmab $GMAB reported Q3 2026 EPS of $5.51, beating the $0.33 estimate by 1569.7%. Revenue of $1.2B missed the $6.7B estimate by 82.2%.

https://fundspec.ai/s/GMAB/earnings
Every headline that matters for your tickers, in one feed.
November 5, 2026 at 9:05 PM
💉 #Epkinly #Darzalex

🇩🇰 #$GMAB Q3 revenue $1,187m, +16%: Epkinly own sales +43%, Darzalex royalties +14%. Profit before tax −27%: R&D +$97m, loan interest $82m. Net −15% at a 3.4% tax rate that Genmab calls not indicative. Guidance kept.

midgardfinance.com/companies/GMAB.CO/
November 5, 2026 at 5:20 PM
💉 #Epkinly #Darzalex

🇩🇰 #$GMAB Q3-omsætning 1.187 mio. $, +16%: Epkinlys eget salg +43%, Darzalex-royalties +14%. Før skat −27%: F&U +97 mio. $, lånerenter 82 mio. $. Netto −15% ved 3,4% skattesats, ikke retningsgivende ifølge Genmab. Guidance uændret.

midgardfinance.com/companies/GMAB.CO/
November 5, 2026 at 5:20 PM
What’s Fueling the Ovarian Cancer Market Boom? Industry to Cross USD 5.7 Billion by 2034 | pharma& GmbH, GlaxoSmithKline, Verastem Oncology, Daiichi Sankyo, AstraZeneca, ProfoundBio, Genmab, Tesaro
https://www.pressreleasecc.com/2026/11/03/whats-fueling-the-ovarian-cancer-market-boom-industry-to-cross-usd-5-7-billion-by-2034-pharma-gmbh-glaxosmithkline-verastem-oncology-daiichi-sankyo-astrazeneca-profoundbio-genmab-t-3
www.pressreleasecc.com
November 4, 2026 at 11:12 PM
What’s Fueling the Ovarian Cancer Market Boom? Industry to Cross USD 5.7 Billion by 2034 | pharma& GmbH, GlaxoSmithKline, Verastem Oncology, Daiichi Sankyo, AstraZeneca, ProfoundBio, Genmab, Tesaro
https://www.pressreleasecc.com/2026/11/03/whats-fueling-the-ovarian-cancer-market-boom-industry-to-cross-usd-5-7-billion-by-2034-pharma-gmbh-glaxosmithkline-verastem-oncology-daiichi-sankyo-astrazeneca-profoundbio-genmab-t-2
www.pressreleasecc.com
November 4, 2026 at 10:12 PM
Signal or noise? > Genmab Stock Price Shock Puts 3 Oncology Biotech Names In
Focus - Yahoo Finance >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharma #competitivemarketing #biotech #pharmaceutical
Genmab Stock Price Shock Puts 3 Oncology Biotech Names In Focus - Yahoo Finance
Genmab Stock Price Shock Puts 3 Oncology Biotech Names In Focus  Yahoo Finance
dlvr.it
November 3, 2026 at 2:58 PM
"Genmab has built its business around antibody-based medicines, including so-called bispecific antibodies such as petosemtamab, which can bind to two different targets on cancer cells simultaneously."
November 3, 2026 at 10:11 AM
"Days earlier, Genmab reported that its medicine Rina-S reduced the risk of disease progression or death by 71% and the risk of death by 57% versus chemotherapy in a Phase 3 ovarian cancer trial."
November 3, 2026 at 10:16 AM
🔥 Genmab etsar marknaden från Eli Lilly med adipositas-läkemedel
#NewsBrief #FINews
Genmab etsar marknaden från Eli Lilly med adipositas-läkemedel
Genmab's tepotinib shows a 15% weight reduction after 72 weeks, competing with Eli Lilly's Mounjaro. This shift in focus from diabetes to obesity is driven by stronger efficacy data and favorable pricing in Europe.
news-brief.com
November 3, 2026 at 12:39 AM